Market Overview:

The influenza diagnostics market is experiencing rapid growth, driven by increasing burden of respiratory illnesses, advancements in molecular and point-of-care technologies, and government initiatives and surveillance programs. According to IMARC Group’s latest research publication, “Influenza Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033”, the global influenza diagnostics market size reached USD 1,014.3 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,614.7 Million by 2033, exhibiting a growth rate (CAGR) of 5.15% during 2025-2033. 

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/influenza-diagnostics-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Influenza Diagnostics Market

• Increasing Burden of Respiratory Illnesses

The substantial and persistent global prevalence of influenza and other respiratory viral infections is a primary market driver. The World Health Organization (WHO) estimates that there are around one billion cases of seasonal influenza annually worldwide, resulting in a considerable number of severe illnesses and significant respiratory-related fatalities each year. This high disease burden, particularly among vulnerable populations such as the elderly and young children, fuels the urgent demand for effective diagnostic tools. Furthermore, the increasing incidence of chronic conditions like COPD and asthma, which heighten the risk of severe flu complications, necessitates routine and timely testing. The need for efficient diagnosis is consistently high, especially during seasonal peaks, driving the consumption of testing kits and reagents globally.

• Advancements in Molecular and Point-of-Care Technologies

Technological innovation, specifically the shift toward highly sensitive molecular assays and decentralized testing, is propelling market growth. Molecular diagnostic assays, such as Reverse Transcription Polymerase Chain Reaction (RT-PCR), offer superior sensitivity and specificity compared to older methods like Rapid Influenza Diagnostic Tests (RIDTs), enabling accurate differentiation of influenza types and subtypes. Concurrently, the increasing availability of CLIA-waived, instrument-free, rapid tests is expanding the adoption of Point-of-Care Testing (POCT) in settings like urgent care centers and pharmacies. This focus on advanced, rapid, and easy-to-use solutions is supported by major industry players like Thermo Fisher Scientific and Abbott Laboratories, which continually launch new, high-throughput systems to meet the demand for swift clinical decision-making.

• Government Initiatives and Surveillance Programs

Proactive governmental actions and substantial investments in public health and disease surveillance are fundamentally bolstering the influenza diagnostics market. Numerous national public health agencies allocate significant funding to monitor influenza outbreaks, track circulating viral strains, and implement early warning systems. For example, the US National Institutes of Health (NIH) has funded the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program to support a broad portfolio of influenza research. Such government and non-profit initiatives not only increase the overall volume of testing conducted but also accelerate the regulatory approval and adoption of advanced diagnostic products, including multiplex panels capable of simultaneously detecting influenza and other common respiratory pathogens like SARS-CoV-2 and RSV.

Key Trends in the Influenza Diagnostics Market

• The Rise of Multiplex Respiratory Panels

A dominant emerging trend is the strong market acceptance and growth of multiplex diagnostic panels that can simultaneously test for multiple respiratory viruses, including influenza A and B, COVID-19 (SARS-CoV-2), and Respiratory Syncytial Virus (RSV), from a single patient sample. This approach is gaining traction because symptoms for these viruses often overlap, making clinical differentiation difficult. The real-world application of this trend is evident in the strategic activities of companies like Roche, which has launched combination rapid antigen tests to aid in quickly distinguishing between these infections at the point of care. This capability streamlines emergency department and hospital workflows, allowing for faster triage and the implementation of appropriate infection control measures, thereby improving patient management during peak respiratory seasons.

• Integration of Diagnostics into Pharmacies and Urgent Care

The decentralization of influenza testing, moving beyond traditional hospital and central laboratory settings into high-volume community and retail locations, represents a significant trend. Point-of-Care (POC) settings, such as pharmacies and urgent care clinics, are experiencing a surge in demand for rapid, accurate, and user-friendly testing platforms. This shift is highlighted by the expansion of retail chains, such as CVS, that are deploying multi-in-one combo tests across hundreds of their clinic locations to provide immediate results. The move to a POC model is supported by devices that offer near-patient molecular testing results in under an hour, facilitating rapid treatment decisions and reducing the risk of community transmission by quickly identifying and isolating positive cases.

• Artificial Intelligence and Data-Driven Surveillance

The incorporation of Artificial Intelligence (AI) and Big Data analytics into the diagnostic workflow is an emerging trend focused on enhancing outbreak prediction and response. While not directly a diagnostic test, AI tools are being used to process, interpret, and automate the quality control of diagnostic results from various sources. This computational power can accelerate the analysis of genetic characterization studies on influenza viruses, enabling researchers to track emerging strains more efficiently. Furthermore, this trend is moving toward real-time epidemiological tracking, where aggregated, anonymous positive test results recorded via smartphone applications could feed into AI-driven models to predict the spread of influenza, providing governments and health organizations with unprecedented, up-to-the-minute data for public health planning.

Leading Companies Operating in the Influenza Diagnostics Industry:

• Abbott Laboratories
• Becton Dickinson and Company
• Cepheid (Danaher Corporation)
• Coris BioConcept
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Meridian Bioscience Inc.
• Qiagen N.V
• QuidelOrtho Corporation
• SEKISUI Diagnostics
• Siemens Healthcare Diagnostics GmbH
• Thermo Fisher Scientific Inc.

Influenza Diagnostics Market Report Segmentation:

By Product:

• Test Kit and Reagents
• Instruments
• Others

Test Kit and Reagents dominate the influenza diagnostics market as they provide essential components for accurate and timely diagnosis of influenza infections.

By Test Type:

• Molecular Diagnostic Tests
• Polymerase Chain Reaction
• Isothermal Nucleic Acid Amplification Tests
• Other Molecular Tests
• Traditional Diagnostic Tests
• Rapid Influenza Diagnostic Tests
• Viral Culture Tests
• Direct Fluorescent Antibody Test
• Serological Tests

Traditional Diagnostic Tests lead the market, offering rapid results essential for quick patient management, despite lower sensitivity compared to molecular tests.

By Type of Flu:

• Type A Flu
• Type B Flu
• Type C Flu

Type A Flu represents the largest segment, encompassing various strains responsible for seasonal outbreaks and potential pandemics, necessitating accurate differentiation for effective treatment.

By End User:

• Hospitals
• Diagnostic Laboratories
• Others

Hospitals dominate the market, providing immediate access to diagnostic services and enabling rapid treatment decisions for patients with flu-like symptoms.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits clear dominance in the influenza diagnostics market, accounting for the largest market share due to robust healthcare infrastructure and demand for diagnostic services.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302